Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment

Eric W Pefura Yone,1,2 Andr&eacute; P Kengne31Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Cameroon; 2Approved Centre for HIV Treatment and Pneumology Service, Yaounde Jamot Hospital, Cameroon; 3South African Medica...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pefura Yone EW, Kengne AP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/d56463ec8eef4830bee8755d36b9fe78
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d56463ec8eef4830bee8755d36b9fe78
record_format	dspace
spelling	oai:doaj.org-article:d56463ec8eef4830bee8755d36b9fe782021-12-02T07:43:24ZClinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment1179-1373https://doaj.org/article/d56463ec8eef4830bee8755d36b9fe782012-12-01T00:00:00Zhttp://www.dovepress.com/clinical-utility-and-consumer-considerations-for-the-use-of-once-daily-a11676https://doaj.org/toc/1179-1373Eric W Pefura Yone,1,2 Andr&eacute; P Kengne31Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Cameroon; 2Approved Centre for HIV Treatment and Pneumology Service, Yaounde Jamot Hospital, Cameroon; 3South African Medical Research Council and University of Cape Town, Cape Town, South AfricaAbstract: An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients&rsquo; adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profiles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiretroviral treatments.Keywords: nevirapine extended release, HIV infection, antiretroviral therapy, efficacy, safetyPefura Yone EWKengne APDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2012, Iss default, Pp 181-184 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Pefura Yone EW Kengne AP Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
description	Eric W Pefura Yone,1,2 Andr&eacute; P Kengne31Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Cameroon; 2Approved Centre for HIV Treatment and Pneumology Service, Yaounde Jamot Hospital, Cameroon; 3South African Medical Research Council and University of Cape Town, Cape Town, South AfricaAbstract: An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients&rsquo; adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profiles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiretroviral treatments.Keywords: nevirapine extended release, HIV infection, antiretroviral therapy, efficacy, safety
format	article
author	Pefura Yone EW Kengne AP
author_facet	Pefura Yone EW Kengne AP
author_sort	Pefura Yone EW
title	Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
title_short	Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
title_full	Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
title_fullStr	Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
title_full_unstemmed	Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
title_sort	clinical utility and consumer considerations for the use of once-daily nevirapine extended release for hiv infection treatment
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/d56463ec8eef4830bee8755d36b9fe78
work_keys_str_mv	AT pefurayoneew clinicalutilityandconsumerconsiderationsfortheuseofoncedailynevirapineextendedreleaseforhivinfectiontreatment AT kengneap clinicalutilityandconsumerconsiderationsfortheuseofoncedailynevirapineextendedreleaseforhivinfectiontreatment
_version_	1718399249740201984

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment

Ejemplares similares